Haisco Pharmaceutical Group Co Ltd
SZSE:002653

Watchlist Manager
Haisco Pharmaceutical Group Co Ltd Logo
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Watchlist
Price: 34.59 CNY -4.45% Market Closed
Market Cap: 38.7B CNY
Have any thoughts about
Haisco Pharmaceutical Group Co Ltd?
Write Note

Haisco Pharmaceutical Group Co Ltd
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Haisco Pharmaceutical Group Co Ltd
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Other Equity
ÂĄ30m
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Equity
ÂĄ136.9m
CAGR 3-Years
N/A
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Equity
ÂĄ2.3m
CAGR 3-Years
-78%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Equity
ÂĄ18.5m
CAGR 3-Years
N/A
CAGR 5-Years
44%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Equity
-ÂĄ36.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Equity
ÂĄ1.4m
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Haisco Pharmaceutical Group Co Ltd
Glance View

Market Cap
38.5B CNY
Industry
Pharmaceuticals

Haisco Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products and medical equipment. The company is headquartered in Shannan, Xizang and currently employs 4,247 full-time employees. The company went IPO on 2012-01-17. The Company’s main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The firm distributes its products in domestic market.

Intrinsic Value
21.19 CNY
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Haisco Pharmaceutical Group Co Ltd's Other Equity?
Other Equity
30m CNY

Based on the financial report for Sep 30, 2024, Haisco Pharmaceutical Group Co Ltd's Other Equity amounts to 30m CNY.

What is Haisco Pharmaceutical Group Co Ltd's Other Equity growth rate?
Other Equity CAGR 5Y
11%

Over the last year, the Other Equity growth was 408%.

Back to Top